The antiplatelet drug clopidogrel is effective when used in combination with aspirin for the prevention of coronary events in patients with coronary artery stents and acute coronary syndromes. However, there is growing evidence that despite this dual antiplatelet therapy some patients experience more atherothrombotic events than expected. 1 This therapeutic failure has been called 'clopidogrel resistance'. The possible factors contributing to variability in the response to clopidogrel include poor adherence, variable bioavailability, drug interactions, and genetic polymorphisms in drug metabolising enzymes or in platelet receptors.
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Clopidogrel is a prodrug and its active metabolite irreversibly binds to and inhibits the adenosine diphosphate P2Y12 receptor on platelets. Approximately 85% of the dose is metabolised to an inactive metabolite (by plasma esterases) and 15% is activated by hepatic cytochrome P450 (CYP) isoenzymes in a two-step metabolic process involving CYP3A4 and CYP2C19. 2 The impact of polymorphisms in the genes that control has also been investigated. Two retrospective studies, involving 13 000 5 and 8000 6 patients, have suggested a clinically significant reduction of efficacy, in terms of recurrent coronary events, in patients treated with clopidogrel if they were also receiving proton pump inhibitors. The effect was modest (approximately 25% increased risk in both studies) and of only borderline statistical significance, suggesting the need for caution in interpreting these results. Pantoprazole does not appear to attenuate clopidogrel's benefits. This has been attributed to its predominant effect on CYP2C9 inhibition and weaker effect on CYP2C19 activity. 5 Suggestions to overcome so-called clopidogrel resistance include the assessment of adherence to clopidogrel therapy, increasing the clopidogrel dose (to increase the amount of active metabolite), screening patients to identify CYP2C19 variants, and avoiding drug interactions with proton pump inhibitors. Welldesigned trials to evaluate the effectiveness of these strategies are lacking, but a recent case series suggested minimal benefits from increasing the clopidogrel dose to as high as 300 mg daily. 9 Routine testing of CYP2C19 allelic variations is not common practice and the risk of adverse effects from increasing the clopidogrel dose requires further investigation. Assessing patient adherence to clopidogrel therapy and avoiding possible drug interactions currently appear to be the most practical strategies.
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Lastly, it remains unclear whether the interaction between proton pump inhibitors and clopidogrel is of clinical significance.
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